(Q33498731)

27 July 2017

title

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck (English)

1 reference

27 July 2017

1 reference

head and neck carcinoma

1 reference

Planting AS

1

1 reference

27 July 2017

de Mulder PH

series ordinal

2

1 reference

27 July 2017

de Graeff A

series ordinal

3

1 reference

27 July 2017

Verweij J

series ordinal

4

1 reference

27 July 2017

publication date

1 January 1997

1 reference

European Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

33

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

61-65

1 reference

A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Induction chemotherapy for advanced head and neck cancers: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Adjuvant chemotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Organ-function preservation in advanced oropharynx cancer: results with induction chemotherapy and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

High-dose cisplatin in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Ototoxicity of low- and moderate-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900311-5

7 January 2021

10.1016/S0959-8049(96)00311-5

Identifiers

DOI

1 reference

27 July 2017

1 reference